Table 2.
Effect of NHL-a101 and NHL-a102 on expression and phosphorylation levels of intracellular signaling proteins.
| Protein short name | Uniprot | Protein name | Phosphorylation site | NHL-a101 vs p17 (%) | NHL-a102 vs p17 (%) |
|---|---|---|---|---|---|
| ABL1 | P00519 | Tyrosine-protein kinase ABL1 | Y393 | +44% | +123% |
| CDK1 | P06493 | Cyclin-dependent kinase 1 | T161 | +60% | +35% |
| CDK2 | P24941 | Cyclin-dependent kinase 2 | – | +2% | +54% |
| CDK4 | P11802 | Cyclin-dependent kinase 4 | – | +27% | −62% |
| CDK6 | Q00534 | Cyclin-dependent kinase 6 | – | +52% | +10% |
| CHEK1 | O14757 | Serine/threonine-protein kinase Chk1 | S280 | +18% | −38% |
| CHEK2 | O96017 | Serine/threonine-protein kinase Chk2 | – | −20% | −2% |
| EGFR | P00533 | Epidermal growth factor receptor | – | −5% | −54% |
| EGFR | P00533 | Epidermal growth factor receptor | T693 | −68% | −94% |
| EGFR | P00533 | Epidermal growth factor receptor | Y998 | +12% | −86% |
| eIF-2A | P19525 | Interferon-induced, double-stranded RNA-activated protein kinase | T446 | −69% | −117% |
| hMSH2 | P43246 | DNA mismatch repair protein Msh2 | – | +42% | +216% |
| JAK1 | P23458 | Tyrosine-protein kinase JAK1 | Y1034 | +22% | −208% |
| MAPK 8 | P45983 | Mitogen-activated protein kinase 8 | – | −11% | +31% |
| NPM | P06748 | Nucleophosmin | S4 | +97% | +22% |
| p53 | P04637 | Cellular tumor antigen p53 | – | −11% | +0% |
| p53 | P04637 | Cellular tumor antigen p53 | S33 | −6% | −127% |
| PTP-1B | P18031 | Tyrosine-protein phosphatase non-receptor type 1 | – | +176% | +1095% |
| RAC1 | P63000 | Ras-related C3 botulinum toxin substrate 1 | – | +11% | +30% |
| RAF1 | P23458 | Tyrosine-protein kinase JAK1 | S259 | −6% | −346% |
| Rb | P06400 | Retinoblastoma-associated protein | S780 | −25% | +111% |
| Rb | P06400 | Retinoblastoma-associated protein | S795 | +55% | +111% |
| STAT1 | P42224 | Signal transducer and activator of transcription 1-alpha/beta | S272 | +27% | +17% |
The protein expression and phosphorylation level were analyzed from Kinexus Bioinformatic Corporation by densitometric analysis of multi-immunoblotting. Blot quantification data of vp17s were compared to refp17 treated samples for the interpretation of the results. The numerical values refer to vp17/refp17 ratio and are expressed as percentage.